ATYR1940

BIOLOGICAL5 trials

Sponsors

aTyr Pharma, Inc.

Conditions

Facioscapulohumeral Muscular DystrophyFacioscapulohumeral Muscular Dystrophy (FSHD)Limb Girdle Muscular DystrophyLimb-Girdle Muscular Dystrophies

Phase 1

Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy

CompletedNCT02239224

aTyr Pharma, Inc.Facioscapulohumeral Muscular Dystrophy (FSHD)

Start: 2014-09-04End: 2015-12-14Updated: 2021-08-11

Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension

CompletedNCT02531217

aTyr Pharma, Inc.Facioscapulohumeral Muscular Dystrophy

Start: 2015-08-13End: 2016-05-26Updated: 2023-08-18

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)

CompletedNCT02579239

aTyr Pharma, Inc.Facioscapulohumeral Muscular Dystrophy, Limb-Girdle Muscular Dystrophies

Start: 2015-11-30End: 2016-10-05Updated: 2023-10-19

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy

CompletedNCT02603562

aTyr Pharma, Inc.Facioscapulohumeral Muscular Dystrophy (FSHD)

Start: 2016-03-30End: 2016-12-12Updated: 2023-10-19

Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)

CompletedNCT02836418

aTyr Pharma, Inc.Facioscapulohumeral Muscular Dystrophy, Limb Girdle Muscular Dystrophy

Start: 2016-07-13End: 2017-04-18Updated: 2023-12-22

Related Papers

Assessment of disease progression in dysferlinopathy

Neurology2019-01-1026 citations

Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD).

2016-08-1714 citations